Pfizer Says European Commission Approves Abrysvo RSV Vaccine for Adults

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Pfizer Says European Commission Approves Abrysvo RSV Vaccine for Adults

, MT Newswires - 3:43 AM ET 4/1/2025 default

03:43 AM EDT, 04/01/2025 (MT Newswires) -- Pfizer ( PFE ) said Tuesday the European Commission approved its Abrysvo vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus, or RSV, in individuals aged 18 to 59.

The Commission granted marketing authorization for the vaccine, which was first approved for adults aged 60 years and older.

The approval is based on a phase 3 clinical trial, which evaluated the safety, tolerability and immunogenicity of the vaccine in patients at risk of RSV-associated lower respiratory tract disease, according to Pfizer ( PFE ).

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.